Poxel (LTS:0RA2) Dividend-Payout-to-FFO

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTS:0RA2 Poxel SA LTS:0RA2
34 GF Score
Price €0.18
GF Value €1.16
Valuation Possible Value Trap
! 6 Warning Signs
View Full Analysis

What is Poxel Dividend-Payout-to-FFO?

Dividend-Payout-to-FFO only applies to REITs.

LTS:0RA2
34GF Score
Poxel SA LTS:0RA2
Dividend-Payout-to-FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Poxel (LTS:0RA2) Overvalued in 2026?

Based on GuruFocus' analysis, Poxel stock appears to be undervalued. The current stock price of €0.18 is trading 84.5% below its estimated GF Value™ of €1.16. GuruFocus considers Poxel to be Possible Value Trap.

Key valuation signals for LTS:0RA2:

  • Dividend-Payout-to-FFO:
  • GF Value™: €1.16 vs. price of €0.18 (84.5% below fair value)
  • GF Score™: 34/100 with 6 warning signs

No single metric tells the full story. See the LTS:0RA2 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Poxel Business Description

Other Exchanges POXEL:France7PO:Germany
Address 259/261 Avenue Jean Jaures, Immeuble le Sunway, Lyon, FRA, 69007
Poxel SA is a French biopharmaceutical company focused on developing novel treatments for metabolic diseases. Its pipeline includes Imeglimin, an oral drug candidate for type 2 diabetes that has been licensed in Japan, and PXL065 and PXL770, candidates targeting nonalcoholic steatohepatitis (NASH) and other metabolic and rare disorders such as adrenoleukodystrophy and adrenomyeloneuropathy. The company operates as a clinical-stage developer, advancing its compounds through preclinical and clinical trials, and generates revenue primarily through licensing and partnership agreements rather than marketed products. Poxel is headquartered in Lyon, France, and has been listed on Euronext Paris. Its activities center on research and development, with collaborations and out-licensing arrangements providing funding and regional commercialization rights for its drug candidates.
34GF Score

Get the complete analysis for LTS:0RA2

Dividend-Payout-to-FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.18
Price
€1.16
GF Value